My INSULIN Act would cap monthly out-of-pocket insulin costs at just $35.
Will cap monthly out-of-pocket insulin costs at $35.
Occurrences
Shaheen announced four new bipartisan cosponsors, bringing the total to 18 bipartisan senators for her bill to cap monthly insulin costs at $35.
The INSULIN Act would cap the cost of insulin at $35 per month for Americans on private and employer insurance and create a pilot program to provide insulin at the same cost to Americans without insurance.
the bipartisan INSULIN Act to cap monthly out-of-pocket costs at $35
We want to make sure that that's available for everyone who has health insurance, that anybody with health insurance knows that they're not going to have to pay more than $35 a month for their insulin.
Shaheen Announces 2 New Cosponsors of Bipartisan Bill to Cap Monthly Insulin Costs at $35, Bringing Total to 28 Bipartisan Senators
Evidence
The senators said the INSULIN Act would cap the cost of insulin at $35 per month for Americans on private and employer insurance and create a pilot program to provide insulin at the same cost to Americans without insurance.
Shaheen’s office said two more senators backed the bipartisan INSULIN Act, bringing the total to 14 co-sponsors; the bill would cap insulin costs at $35 per month for Americans on private and employer insurance and create a pilot for the uninsured.
Shaheen's June 8, 2026 press release says four new senators joined her bill to cap monthly insulin costs at $35, bringing the total to 22 bipartisan senators, and describes the measure as a bill rather than enacted law.
Shaheen's office said the INSULIN Act was being introduced to cap insulin at $35 per month for people on private and employer insurance and to create a $35 insulin pilot for uninsured Americans, with senators urging Congress to pass the bill.
The bill text for the INSULIN Act of 2026 would limit cost-sharing for selected insulin products to no more than $35 per 30-day supply in the applicable plan years and was introduced in the Senate for referral to committee.
Shaheen reported that four more senators joined the INSULIN Act, bringing support to 22 bipartisan senators, while still describing the measure as a bill to cap monthly insulin costs at $35.
Assessments
Shaheen materially advanced the promised $35 insulin cap by introducing and building bipartisan support for the INSULIN Act, but the evidence shows the policy remained proposed legislation in 2026 rather than enacted federal law. Because she made a serious legislative effort without achieving the promised outcome, this is best scored as a failed delivery with effort credit, and the activity reflected in the record occurred in a later phase rather than immediate delivery.
Shaheen clearly made a serious legislative effort to achieve a $35 monthly insulin out-of-pocket cap by introducing and building bipartisan support for the INSULIN Act in 2026. But the provided evidence describes the measure only as an active bill with growing cosponsorship, not enacted law or an implemented cap. Under the stated rules, a substantial attempt without actual delivery counts as never, with the effort badge set to true.
A $35 monthly insulin out-of-pocket cap was enacted for Medicare beneficiaries through the Inflation Reduction Act during Shaheen's current Senate term, and as a sitting senator she had federal voting/legislative credit for that outcome. However, the broader promise is not fully delivered for all insulin users: Shaheen's later INSULIN Act efforts in 2026 seek to extend a $35 cap to private/employer insurance and create an uninsured pilot, but those proposals have not been enacted. This supports partial fulfillment rather than full delivery.